Frequency of TERT promoter mutations in human cancers

Cited by (886)

Items 201–300 of 886

1. P athogenic and targetable genetic alterations in 70 urachal adenocarcinomas
   Henning Reis, Kristan E. van der Vos, Christian Niedworok, Thomas Herold, Orsolya Módos, Attila Szendrői, Thomas Hager, Marc Ingenwerth, Daniël J. Vis, Mark A. Behrendt et al. · 2018 · International Journal of Cancer
2. Mutation profiles of follicular thyroid tumors by targeted sequencing
   Huanli Duan, Xiaoding Liu, Xinyu Ren, Hui Zhang, Huanwen Wu, Zhiyong Liang · 2019 · Diagnostic Pathology
3. Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
   Nazlı Dizman, Yung Lyou, Nicholas Salgia, Paulo Gustavo Bergerot, Joann Hsu, Daniel Enriquez, Tyler Izatt, Jeffrey M. Trent, Sara Ann Byron, Sumanta Kumar Pal · 2020 · Journal for ImmunoTherapy of Cancer
4. ENDOCRINE TUMOURS: Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genome
   Garcilaso Riesco‐Eizaguirre, Pilar Santisteban · 2016 · European Journal of Endocrinology
5. TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis
   Chunping Liu, Zeming Liu, Tianwen Chen, Wen Zeng, Yawen Guo, Tao Huang · 2016 · Scientific Reports
6. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data
   Huy Gia Vuong, Ahmed M. A. Altibi, Uyen N.P. Duong, Hanh Thi Tuyet Ngo, Thong Quang Pham, Aden Ka‐Yin Chan, Chul‐Kee Park, Kar-Ming A. Fung, Lewis Allen Hassell · 2017 · Critical Reviews in Oncology/Hematology
7. TERT promoter mutations in solitary fibrous tumour
   Elizabeth G. Demicco, Khalida Wani, Davis R. Ingram, Michael J. Wagner, Robert G. Maki, Anthony J. Rizzo, Alan Keith Meeker, Alexander J. Lazar, Wei‐Lien Wang · 2018 · Histopathology
8. Expression level ofhTERTis regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma
   Chul‐Kee Park, Se‐Hoon Lee, Ji Young Kim, Ja‐Eun Kim, Tae Min Kim, Soon‐Tae Lee, Seung Hong Choi, Sung‐Hye Park, Il Han Kim · 2014 · Oncotarget
9. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma
   Emilia Hugdahl, May Britt Kalvenes, Monica Mannelqvist, Rita Grude Ladstein, Lars A. Akslen · 2017 · British Journal of Cancer
10. The genetic landscape of choroid plexus tumors in children and adults
    Christian Thomas, Patrick Soschinski, Melissa Zwaig, Spyridon Oikonomopoulos, Konstantin Okonechnikov, Kristian W. Pajtler, Martin Sill, Leonille Schweizer, Arend Koch, Julia E. Neumann et al. · 2020 · Neuro-Oncology
11. Uterine PEComas: correlation between melanocytic marker expression and TSC alterations/TFE3 fusions
    Jennifer A. Bennett, Zehra Ordulu, André Pinto, Pankhuri Wanjari, Cristina R. Antonescu, Lauren L. Ritterhouse, Esther Oliva · 2021 · Modern Pathology
12. Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta‐analysis
    Detao Yin, Kun Yu, Runqing Lu, Xianghua Li, Jianhui Xu, Mengyuan Lei, Hongqiang Li, Yongfei Wang, Zhen Liu · 2016 · Clinical Endocrinology
13. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism
    Rui Batısta, Adriana Cruvinel‐Carloni, João Vinagre, Joana Peixoto, Telmo A. Catarino, Nathália Cristina Campanella, Weder Pereira de Menezes, Aline Paixão Becker, Gisele Caravina de Almeida, Marcus Matsushita et al. · 2016 · International Journal of Cancer
14. Genetic predisposition to melanoma
    Jason Ezra Hawkes, Amanda Truong, Laurence J. Meyer · 2016 · Seminars in Oncology
15. Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients
    Heera Yang, Hyunju Park, Hyun Jin Ryu, Jung Heo, Jung-Sun Kim, Young Lyun Oh, Jun‐Ho Choe, Hyun Jung Kim, Jee Soo Kim, Hye Won Jang et al. · 2022 · Endocrinology and Metabolism
16. Predicting survival in glioblastoma with multimodal neuroimaging and machine learning
    Patrick H. Luckett, Michael O. Olufawo, Bidhan Lamichhane, Ki Yun Park, Donna L. Dierker, Gabriel Trevino Verastegui, Peter H Yang, Albert H. Kim, Milan G. Chheda, Abraham Z. Snyder et al. · 2023 · Journal of Neuro-Oncology
17. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas
    Vinícius de Lima Vazquez, Anna Luiza Silva Almeida Vicente, Adriana Cruvinel Carloni, Gustavo Nóriz Berardinelli, Paula Soares, Cristovam Scapulatempo‐Neto, Olga Martinho, Rui Manuel Reis · 2015 · Melanoma Research
18. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation
    Almira Nasirden, Tsuyoshi Saito, Yuki Fukumura, Kieko Hara, Keisuke Akaike, Aiko Kurisaki‐Arakawa, Miki Asahina, Atsushi Yamashita, Ran Tomomasa, Takuo Hayashi et al. · 2016 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
19. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma
    Kai‐Ping Chang, Chun‐I Wang, Curtis R. Pickering, Yenlin Huang, Chi‐Neu Tsai, Ngan‐Ming Tsang, Huang‐Kai Kao, Ming‐Huei Cheng, Jeffrey N. Myers · 2017 · Head & Neck
20. Telomerase reverse transcriptase mutations are independent predictor of disease‐free survival in M iddle E astern papillary thyroid cancer
    Rong Bu, Abdul K. Siraj, Sasidharan Padmaja Divya, Yan Kong, Sandeep Kumar Parvathareddy, Maha M. Al-Rasheed, Khadija A.S. Al‐Obaisi, Ingrid G. Victoria, Saif S. Al-Sobhi, Mohammed Aldawish et al. · 2017 · International Journal of Cancer
21. Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms
    Dustin T. Proctor, Sudheesh Ramachandran, Sanju Lama, Garnette Roy Sutherland · 2018 · World Neurosurgery
22. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma
    Claire Bournaud, Françoise Descôtes, Myriam Decaussin‐Petrucci, Julien Berthiller, Christelle de la Fouchardière, Anne‐Laure Giraudet, Mireille Bertholon-Grégoire, Philip Robinson, Jean‐Christophe Lifante, Jonathan Lopez et al. · 2019 · European Journal of Cancer
23. Telomere function and regulation from mouse models to human ageing and disease
    Corey Winston Jones-Weinert, Laura Mainz, Jan Karlseder · 2024 · Nature Reviews Molecular Cell Biology
24. TERT aberrancies: a screening tool for malignancy in follicular thyroid tumours
    Johan O. Paulsson, Ninni Mu, Ivan Shabo, Na Wang, Jan Zedenius, Catharina Larsson, C. Christofer Juhlin · 2018 · Endocrine Related Cancer
25. Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis
    Haoyu Ren, Yifan Shen, Daixing Hu, Wei He, Jing Zhou, Yijia Cao, Yu Mao, Yi Dou, Wei Xiong, Qi Xiao et al. · 2018 · Cancer Management and Research
26. Genetic profiling as a clinical tool in advanced parathyroid carcinoma
    Merve Kutahyalioglu, Há Thi Nguyen, Lily Joy Kwatampora, Callisia Nathelee Clarke, Angelica M. Silva-Figueroa, Eiman Ibrahim, Steven Gerard Waguespack, Maria E. Cabanillas, Camilo Jiménez, Mimi I-Nan Hu et al. · 2019 · Journal of Cancer Research and Clinical Oncology
27. Malignant phyllodes tumors of the breast: A comprehensive literature review
    Yasmine Papas, Antoine El Asmar, Fatmeh Ghandour, Imad El Hajj · 2019 · The Breast Journal
28. Molecular mutations as a possible factor for determining extent of thyroid surgery
    Joshua R. Krasner, Nourah Alyouha, Marc Philippe Pusztaszeri, Véronique‐Isabelle Forest, Michael P. Hier, Galit Avior, Richard J. Payne · 2019 · Journal of Otolaryngology - Head and Neck Surgery
29. BRAF and TERT promoter mutations: clinical application in thyroid cancer
    Jae Hoon Chung · 2020 · Endocrine Journal
30. Cancer-Associated Mutations but No Cancer: Insights into the Early Steps of Carcinogenesis and Implications for Early Cancer Detection
    Scott R. Kennedy, Yuezheng Zhang, Rosa Ana Risques · 2019 · Trends in cancer
31. Pan-cancer analysis of somatic mutations in miRNA genes
    Martyna Olga Urbanek-Trzeciak, Paulina Galka-Marciniak, Paulina Maria Nawrocka, Ewelina Kowal-Wiśniewska, Sylwia Szwec, Maciej Giefing, Piotr Kozłowski · 2020 · EBioMedicine
32. Telomere length and the risk of cutaneous melanoma and non-melanoma skin cancer: a review of the literature and meta-analysis
    Saverio Caini, Sara Raimondi, Harriet Ann Johansson, Vincenzo DE GIORGI, Ines Zanna, Domenico Palli, Sara Gandini · 2015 · Journal of Dermatological Science
33. TERT promoter mutations in clear cell renal cell carcinoma
    Md. Ismail Hosen, P. Sivaramakrishna Rachakonda, Barbara Heidenreich, Raviprakash Tumkur Sitaram, Börje Ljungberg, Göran Roos, Kari Hemminki, Rajiv Kumar · 2014 · International Journal of Cancer
34. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer
    Seo Young Sohn, Woong‐Yang Park, Hyun‐Tae Shin, Joon Seol Bae, Chang‐Seok Ki, Young Lyun Oh, Sun Wook Kim, Jae Hoon Chung · 2016 · Thyroid
35. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations
    Matthew M. Makowski, Esther Willems, Jun Fang, Jiyeon Choi, Tongwu Zhang, Pascal W.T.C. Jansen, Kevin M. Brown, Michiel Vermeulen · 2015 · PROTEOMICS
36. Non-coding genetic variation in cancer
    Tawny N. Cuykendall, Mark A. Rubin, Ekta Khurana · 2017 · Current Opinion in Systems Biology
37. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma
    Ashleigh Cavell McEvoy, Leslie Calapre, Michelle R. Pereira, Tindaro M. Giardina, Cleo Robinson, Muhammad Adnan Khattak, Tarek M. Meniawy, Antonia L. Pritchard, Nicholas K. Hayward, Benhur Amanuel et al. · 2017 · Oncotarget
38. Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials
    Nicola Relitti, Akella Prasanth Saraswati, Stefano Federico, Tuhina Khan, Margherita Brindisi, Daniela M. Zisterer, Simone Brogi, Sandra Gemma, Stefania Butini, Giuseppe Campiani · 2020 · Current Topics in Medicinal Chemistry
39. Prognostic biomarkers in thyroid cancer
    Paula Soares, Ricardo Celestino, Miguel Melo, Elsa Fonseca, Manuel A. Sobrinho-Simões · 2014 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
40. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population
    Ebtesam Qasem, Avaniyapuram Kannan Murugan, Hindi Al‐Hindi, Mingzhao Xing, Mai Almohanna, Meshael M. Alswailem, Ali Saeed Alzahrani · 2015 · Endocrine Related Cancer
41. Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma
    Tatenda Mahlokozera, Ananth Kesav Vellimana, Tiandao Li, Diane D. Mao, Zohny S. Zohny, David H. Kim, David Dinh Tran, Daniel S. Marcus, Sarah Jost Fouke, Jian Li Campian et al. · 2017 · Neuro-Oncology
42. Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation
    Ilaria J. Russo, Yongwon Ju, Naheema S. Gordon, Maurice Petrus Zeegers, Kar Keung Cheng, Nicholas David James, Richard T. Bryan, Douglas G. Ward · 2018 · Bladder Cancer
43. Knockdown of linc-OIP5 inhibits proliferation and migration of glioma cells through down-regulation of YAP-NOTCH signaling pathway
    Guowen Hu, Lei Wu, Wei Kuang, Yong Chen, Xin-gen Zhu, Hua Guo, Haili Lang · 2017 · Gene
44. The Solo Play of TERT Promoter Mutations
    François Hafezi, Danielle Perez-Bercoff · 2020 · Cells
45. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management
    Liang Cheng C, Shaobo Zhang, Mingsheng Wang, Antonio Lopez-beltran B · 2022 · Human Pathology
46. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF V600E Harboring Pediatric Papillary Thyroid Carcinomas
    Semen Yeşil Önder, Şule Öztürk Sarı, Gülçin Yeğen, İsmail Cem Sormaz, İsmail Yılmaz, Şükran Poyrazoğlu, Yasemin Şanlı, Yasemin Giles Senyurek, Yersu Kapran, Özgür Mete · 2016 · Endocrine Pathology
47. Whole Genome Analysis of Ovarian Granulosa Cell Tumors Reveals Tumor Heterogeneity and a High-Grade TP53-Specific Subgroup
    Joline F. Roze, Glen R. Monroe, Joachim Kutzera, Jolijn W. Groeneweg, Ellen Stelloo, Sterre T. Paijens, Hans W. Nijman, Hannah S. van Meurs, Luc R.C.W. van Lonkhuijzen, Jurgen M.J. Piek et al. · 2020 · Cancers
48. Time to re‐consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma
    Greta Gandolfi, Valentina Sancisi, Simonetta Piana, Alessia Ciarrocchi · 2014 · International Journal of Cancer
49. Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells
    Yohan Suryo Rahmanto, Jin-Gyoung Jung, Ren‐Chin Wu, Yusuke Kobayashi, Christopher M. Heaphy, Alan Keith Meeker, Tian‐Li Wang, Ie‐Ming Shih · 2016 · Journal of Biological Chemistry
50. TERT promoter mutations and gene amplification: Promoting TERT expression in Merkel cell carcinoma
    Hong Yu Xie, Tiantian Liu, Na Wang, Viveca Björnhagen, Anders Höög, Catharina Larsson, Weng‐Onn Lui, Dawei Xu · 2014 · Oncotarget
51. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications
    Boaz Kurtis, Jian Zhuge, Caroline Ojaimi, Fei Ye, Dongming Cai, David Zhang, John T. Fallon, Minghao Zhong · 2015 · Annals of Diagnostic Pathology
52. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer
    Anqi Jin, Jianhao Xu, Yan Wang · 2018 · Medicine
53. A comprehensive expression landscape of RNA-binding proteins (RBPs) across 16 human cancer types
    Bin Zhang, Kamesh R. Babu, Chun You Lim, Zhi Hao Kwok, Jia Li, Siqin Zhou, Henry He Yang, Yvonne Tay · 2019 · RNA Biology
54. Application of molecular biology of differentiated thyroid cancer for clinical prognostication
    Vincenzo Marotta, Concetta Sciammarella, Annamaria Colao, Antongiulio Faggiano · 2016 · Endocrine Related Cancer
55. Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma
    Maria Isabel Carlo, Brandon J. Manley, Sujata Patil, Kaitlin M. Woo, Devyn Taylor Coskey, Almedina Redzematovic, Maria E. Arcila, Marc Ladanyi, Won‐Jae Lee, Ying‐Bei Chen et al. · 2017 · Kidney Cancer
56. Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma
    Maxime Fontanilles, Florent Marguet, Ludivine Beaussire, Nicolas Magné, Louis‐Ferdinand Pépin, Cristina Alexandru, Isabelle Tennevet, C. Hanzen, Olivier Langlois, Fabrice Jardin et al. · 2020 · Acta Neuropathologica Communications
57. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics
    Zhicong Li, Lena Kaiser, Adrien Holzgreve, Viktoria Ruf, Bogdana Suchorska, Vera Wenter, Stefanie Quach, Jochen Wolfgang Herms, Peter Bartenstein, Jörg‐Christian Tonn et al. · 2021 · European Journal of Nuclear Medicine and Molecular Imaging
58. Prognostic biomarkers of cutaneous melanoma
    Liang Ding, Alexandra Gosh, Delphine J. Lee, Gabriella Emri, Wendy J. Huss, Paul N. Bogner, György Paragh · 2022 · Photodermatology Photoimmunology & Photomedicine
59. Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi
    Yiping Fan, Seung Jae Lee, Gang Wu, John B. Easton, Donald Albert Yergeau, Reinhard Dummer, Peter Vogel, John M. Kirkwood, Raymond L. Barnhill, Alberto S. Pappo et al. · 2015 · Journal of Investigative Dermatology
60. Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
    Dagmara Rusinek, Ewa Chmielik, Jolanta Krajewska, Michał Jarząb, Małgorzata Oczko‐Wojciechowska, Agnieszka Czarniecka, Barbara Jarząb · 2017 · International Journal of Molecular Sciences
61. Emerging mechanisms of telomerase reactivation in cancer
    Shalu Sharma, Shantanu Chowdhury · 2022 · Trends in cancer
62. Interpretation of allele-specific chromatin accessibility using cell state–aware deep learning
    Atak, Zeynep Kalender, Taskiran, Ibrahim Ihsan, Demeulemeester, Jonas, Flerin, Christopher, Mauduit, David, Minnoye, Liesbeth, Hulselmans, Gert, Christiaens, Valerie, Ghanem, Ghanem-Elias, Wouters, Jasper et al. · 2021 · Genome Research
63. The Mutational Landscape in Pediatric Acute Lymphoblastic Leukemia Deciphered by Whole Genome Sequencing
    Carl Mårten Lindqvist, Jessica Nordlund, Diana Stark Ekman, Anna Johansson, Behrooz Torabi Moghadam, Amanda Raine, Elin Övernäs, Johan Dahlberg, Per Wahlberg, Niklas Henriksson et al. · 2014 · Human Mutation
64. TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer
    Mathilde Gay‐Bellile, Lauren Véronèse, Patricia Combes, Éléonore Eymard-Pierre, Fabrice Kwiatkowski, Marie-Mélanie Dauplat, Anne Cayre, Maud Privat, Catherine Abrial, Yves‐Jean Bignon et al. · 2017 · Oncotarget
65. TERT promoter hotspot mutations in breast cancer
    Tatsunori Shimoi, Masayuki Yoshida, Yuka Kitamura, Tomomi Yoshino, Asuka Kawachi, Akihiko Shimomura, Emi Noguchi, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu et al. · 2017 · Breast Cancer
66. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis
    Nancy E. Thomas, Sharon N. Edmiston, Yi‐Hsuan Tsai, Joel S. Parker, Paul B. Googe, Klaus Johannes BUSAM, GLYNIS A. SCOTT, Daniel C. Zedek, Eloise Parrish, Honglin Hao et al. · 2018 · American Journal of Dermatopathology
67. Dysregulation of cancer genes by recurrent intergenic fusions
    Jae Won Yun, Lixing Yang, Hye-Young Park, Chang‐Woo Lee, Hongui Cha, Hyun‐Tae Shin, Ka‐Won Noh, Yoon‐La Choi, Woong‐Yang Park, Peter J. Park · 2020 · Genome biology
68. Evolving Molecular Genetics of Glioblastoma
    Qiu-Ju Li, Jinquan Cai, Cheng-yin Liu · 2016 · Chinese Medical Journal
69. Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma
    Jozefina Casuscelli, Maria F. Becerra, Brandon J. Manley, Emily Craig Zabor, Ed Reznik, Almedina Redzematovic, Maria E. Arcila, Daniel M. Tennenbaum, Mazyar Ghanaat, Mahyar Y. Kashan et al. · 2017 · European Urology Focus
70. TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment
    Huahua Li, Jia Li, Chenyue Zhang, Chenxing Zhang, Haiyong Wang · 2020 · Cancer Medicine
71. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer
    Francesco De Sanctis, Alessia Lamolinara, Federico Boschi, Chiara Musiu, Simone Caligola, Rosalinda Trovato, Alessandra Fiore, Cristina Frusteri, Cristina Anselmi, Ornella Poffe et al. · 2022 · Journal for ImmunoTherapy of Cancer
72. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas
    Vilvanathan Vinothkumar, Ganesan Arunkumar, Sundaramoorthy Revathidevi, Kanagaraj Arun, Mayakannan Manikandan, Arunagiri Kuha Deva Magendhra Rao, Rajkumar Kottayasamy Seenivasagam, Chandrasekar Ajay, Ramamurthy Rajaraman, Rajendren Ramani et al. · 2015 · Tumor Biology
73. TERT promoter mutation is uncommon in acral lentiginous melanoma
    Jau‐Yu Liau, Jia‐Huei Tsai, Yung‐Ming Jeng, Chia‐Yu Chu, Kuan‐Ting Kuo, Cher‐Wei Liang · 2014 · Journal of Cutaneous Pathology
74. Activation of human telomerase reverse transcriptase through gene fusion in clear cell sarcoma of the kidney
    Jenny Karlsson, Henrik Lilljebjörn, Linda Holmquist Mengelbier, Anders Valind, Marianne Rissler, Ingrid Øra, Thoas Fioretos, David Gisselsson · 2014 · Cancer Letters
75. Papillary Thyroid Microcarcinoma
    Paula Soares, Ricardo Celestino, Adriana Gaspar da Rocha, Manuel A. Sobrinho-Simões · 2014 · International Journal of Surgical Pathology
76. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low‐grade astrocytoma
    Nozomi Matsumura, Nozomi Nakajima, Tatsuya Yamazaki, Takuro Nagano, Kaie Kagoshima, Sumihito Nobusawa, Hayato Ikota, Hideaki Yokoo · 2016 · Neuropathology
77. Human Specific Regulation of the Telomerase Reverse Transcriptase Gene
    Fan Zhang, De Cheng, Shuwen Wang, Jiyue Zhu · 2016 · Genes
78. Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues
    Ashleigh Cavell McEvoy, Benjamin Andrew Wood, Nima Mesbah Ardakani, Michelle R. Pereira, Robert Pearce, Lester Cowell, Cleo Robinson, Fabienne Grieu‐Iacopetta, Alexander James Spicer, Benhur Amanuel et al. · 2018 · Journal of Molecular Diagnostics
79. Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma
    Hueng‐Chuen Fan, Chuan‐Mu Chen, Ching-Shiang Chi, Jeng‐Dau Tsai, Kuo-Liang Chiang, Yu‐Kang Chang, Shinn‐Zong Lin, Horng‐Jyh Harn · 2019 · International Journal of Molecular Sciences
80. A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing
    Sounak Gupta, Chad Vanderbilt, Yun-Te Lin, Jamal K. Benhamida, Achim A. Jungbluth, Satshil Rana, Amir Momeni Boroujeni, Jason C. Chang, Tiffany Mcfarlane, Paulo A. Salazar et al. · 2020 · Journal of Molecular Diagnostics
81. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
    Gao Zhang, Lawrence Wen Wu, Ilgen Mender, Michal Barzily-Rokni, Marc R. Hammond, Omotayo Ope, Chaoran Cheng, Themistoklis Vasilopoulos, Sergio Randell, Norah Layla Sadek et al. · 2018 · Clinical Cancer Research
82. Telomere sequence content can be used to determine ALT activity in tumours
    Michael Lee, Erdahl Teber, Oliver Holmes, Kátia Nones, Ann‐Marie Patch, Rebecca A. Dagg, Loretta M. S. Lau, Joyce H. Y. Lee, Christine E. Napier, Jonathan W. Arthur et al. · 2018 · Nucleic Acids Research
83. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer
    Tomasz Trybek, Agnieszka Walczyk, Danuta Gąsior‐Perczak, Iwona Pałyga, Estera Mikina, Artur Kowalik, Kinga Hińcza, Janusz Kopczyński, Magdalena Chrapek, Stanisław S. Góźdź et al. · 2019 · Endocrinology
84. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma
    Christian Thomas, Felix Thierfelder, Malte Träger, Patrick Soschinski, Michael Müther, Dominic Edelmann, Alexandra Förster, Carola Geiler, Hee‐Yeong Kim, Katharina Filipski et al. · 2021 · Acta Neuropathologica
85. Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential
    Espen B. Ellingsen, Sara M. Mangsbo, Eivind J. Hovig, Gustav Gaudernack · 2021 · Frontiers in Immunology
86. Progress in Thyroid Cancer Genomics: A 40-Year Journey
    James A. Fagin, Yuri E. Nikiforov · 2023 · Thyroid
87. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia
    Thomas G. Papathomas, Lindsey Oudijk, Ellen C. Zwarthoff, Edward Post, Floor A.M. Duijkers, Max Maria van Noesel, Leo J. Hofland, Patrick J. Pollard, Eamonn Richard Maher, David F. Restuccia et al. · 2014 · Endocrine Related Cancer
88. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma
    Zheming Lu, Yujie Zhang, Dongdong Feng, Jindong Sheng, Wenjun Yang, Baoguo Liu · 2017 · Oncotarget
89. Non-canonical roles of canonical telomere binding proteins in cancers
    Semih Can Akıncılar, Claire Hian Tzer Chan, Qin Feng Ng, Kerem Fidan, Vinay Tergaonkar · 2021 · Cellular and Molecular Life Sciences
90. Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
    Espen B. Ellingsen, Elin Aamdal, Tormod Kyrre Guren, Wolfgang A. Lilleby, Paal Fredrik Brunsvig, Sara M. Mangsbo, Steinar Aamdal, Eivind J. Hovig, Nadia Mensali, Gustav Gaudernack et al. · 2022 · Journal for ImmunoTherapy of Cancer
91. Telomere biology and translational research
    Philip J. Mason, Nieves Perdigones · 2013 · Translational research
92. TERT Promoter Mutations Lead to High Transcriptional Activity under Hypoxia and Temozolomide Treatment and Predict Poor Prognosis in Gliomas
    Chen Chen, Sheng Han, Lingxuan Meng, Zhonghua Li, Xue Zhang, Anhua Wu · 2014 · PLoS ONE
93. Telomerase-Dependent and Independent Telomere Maintenance and its Clinical Implications in Medullary Thyroid Carcinoma
    Na Wang, Dawei Xu, Anastasios Sofiadis, Anders Höög, Vladana B. Vukojević, Martin Bäckdahl, Jan Zedenius, Catharina Larsson · 2014 · The Journal of Clinical Endocrinology & Metabolism
94. Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis
    Jiang‐Jiang Qin, Wei Wang, Sushanta Sarkar, Ruiwen Zhang · 2016 · Journal of Controlled Release
95. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma
    Manuel António Costa Campos, Sofia Macedo, Margarida Sá Fernandes, Ana Pestana, Joana Pardal, Rui Batısta, João Vinagre, Agostinho Sanches, Armando Baptista, José Manuel Lopes et al. · 2018 · Journal of the American Academy of Dermatology
96. Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy
    Daniele Lombardo, Carlo Saitta, Domenico Giosa, Francesca Casuscelli di Tocco, Cristina Musolino, Giuseppe Caminiti, Valeria Chines, Maria Stella Franzè, Angela Alibrandi, Giuseppe Navarra et al. · 2020 · Oncology Letters
97. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer
    Yujiro Hayashi, Kazutoshi Fujita, Kyosuke Matsuzaki, Marie‐Lisa Eich, Eisuke Tomiyama, Makoto Matsushita, Yoko Koh, Kosuke Nakano, Cong Wang, Yu Ishizuya et al. · 2020 · Frontiers in Oncology
98. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma
    Doreen N. Nguyen, Diana Taheri, Simeon U. Springer, Morgan L. Cowan, Güneş Güner, Maria Angélica Mendoza Rodriguez, Yuxuan Wang, Isaac Kinde, Christopher J. VandenBussche, Matthew T. Olson et al. · 2016 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
99. Molecular landscape of Hereditary Melanoma
    Joyce Ribeiro Moura Brasil Arnaut, Isabella dos Santos Guimarães, Anna Cláudia Evangelista dos Santos, Flora de Moraes Lino da Silva, Jorge Ricardo da Silva Machado, Andréia Cristina de Melo · 2021 · Critical Reviews in Oncology/Hematology
100. Telomerase as a therapeutic target in glioblastoma
     Elisa Aquilanti, Lauren Kageler, Patrick Yung Wen, Matthew M. Meyerson · 2021 · Neuro-Oncology